经皮冷冻消融治疗100例肾前部肿瘤:安全性与技术成功率
回顾性分析2008至2022年100例肾前部肿瘤患者接受CT引导经皮冷冻消融,平均肿瘤最大径29 mm,92%获初期技术成功、98%获二期技术成功,4%发生主要不良事件,8%局部复发,1年总生存率94%、肿瘤特异性生存率100%。
要点
- 肾前部肿瘤CT引导经皮冷冻消融技术成功率高:初期92%、二期98%。
- 主要不良事件4%,包括需延长住院、输血或栓塞的出血及需引流的肾周脓肿。
- 8%局部复发,复发者均再次消融且未再复发;1年总生存率94%、肿瘤特异性生存率100%。
核心结论
- 肾前部肿瘤的经皮冷冻消融可安全实施,并具有较高的技术和肿瘤学成功率。
研究设计与样本
- 回顾性分析2008至2022年接受CT引导经皮冷冻消融的肾前部肿瘤(位于肾盂水平或更前方)患者,共100例患者、100个肿瘤,平均年龄63岁、平均BMI 33、平均Charlson共病指数6。
诊断标准与关键数值
- 78%肿瘤为T1a、22%为T1b,平均肿瘤最大径29 mm(范围6-62 mm),距最近关键结构平均距离9 mm(范围0-40 mm);初期技术成功92%,二期技术成功98%;主要不良事件4%、次要不良事件27%;局部复发8%;1年总生存率94%、肿瘤特异性生存率100%。
临床应用与阅片要点
- 28%的经皮冷冻消融需水分离;8例复发中3例(38%)为T1b、5例(63%)为T1a肿瘤,所有复发均再次消融且未再复发。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess the safety, technical success, and clinical outcomes of percutaneous cryoablation (PCA) in patients with anterior renal tumors.
METHODS: A retrospective analysis of patients with anterior renal tumors, defined as tumors at or anterior to the level of the renal pelvis, treated with CT-guided PCA from 2008 to 2022. Summary statistics included demographics and baseline tumor attributes. Treatment and follow-up metrics included primary and secondary technical success, adverse events (AEs) according to the SIR classification, local recurrence, overall survival (OS), and cancer-specific survival (CSS)). 100 patients (60 males; mean age: 63, mean BMI: 33, mean Charlson comorbidity index:6) with 100 anterior renal tumors were included.
RESULTS: 78% of tumors were T1a and 22% T1b with mean maximal tumoral dimension of 29 mm (range: 6-62 mm) and mean distance to nearest critical structure 9 mm (range: 0-40 mm). Mean follow-up was 20.9 months (range: 3-103). 28% of PCAs required hydrodissection. Technical success was achieved in 92% of patients; with six remaining patients undergoing successful repeat PCA (secondary technical success: 98%). The remaining two patients without primary technical success were either surveilled or had a benign pathology on resulted concomitant biopsy. Four patients (4%) had major AEs (hemorrhage requiring prolonged admission, transfusion, or embolization (n = 3), perinephric abscess requiring drainage (n = 1)) and 27% had minor AEs. Eight patients (8%) had recurrence with a one-year OS of 94% and CSS of 100%. All recurrences underwent repeat ablation without additional recurrence and 3/8 (38%) were T1b and 5/8 (63%) were T1a tumors.
CONCLUSION: PCA of anterior renal tumors can be performed safely with high rates of technical and oncologic success.
引用
- Raja J, Pigg R, Li Y, et al. Percutaneous cryoablation of 100 anterior renal tumors: safety and technical success. Abdom Radiol (NY). 2023. PMID: 38150142. doi:10.1007/s00261-023-04134-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。